CALL - SPRINTER OPEN END - BIOGEN IDEC | Delayed Deutsche Boerse AG 13:44:14 2024-05-23 EDT | ||
| 2.79 EUR | -20.51% |
|
| Current month | +2.95% | ||
| 1 month | +335.94% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-05-23 | 2.79 | -20.51% |
| 24-05-22 | 3.51 | +0.29% |
| 24-05-21 | 3.5 | -14.00% |
| 24-05-20 | 4.07 | +7.39% |
| 24-05-17 | 3.79 | -1.04% |
Delayed Quote Deutsche Boerse AG
Last update May 23, 2024 at 01:44 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VX7HCZ |
| ISIN | DE000VX7HCZ8 |
| Date issued | 2022-02-22 |
| Strike | 190.7 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.87 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14 € |
|---|---|
| Lowest since issue | 0.23 € |
| Spread | 0.21 € |
| Spread % | 7.19% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
218.1
USD
Average target price
286.1
USD
Spread / Average Target
+31.18%
- Stock Market
- Certificates
- Certificat
